CMS Ended Expedited Medicare Pay for Breakthrough Devices
Medical device manufacturers face stricter requirements for Medicare add-on payments as special status pathways close.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Should medical devices receive expedited Medicare funding without proving substantial clinical improvement over existing alternatives?
In August 2026, the Centers for Medicare and Medicaid Services finalized the removal of expedited payment pathways for FDA-designated breakthrough devices. New devices with this designation will no longer qualify for supplementary Medicare payments starting October 2026.
Why it matters
This policy shift eliminates a streamlined reimbursement route that previously allowed devices to bypass requirements for proving substantial clinical improvement. Businesses must now prepare for more rigorous documentation and evidence standards to secure Medicare coverage and payment.
The FDA breakthrough device designation program, which captured nearly 800 devices on the STAT tracker since 2022, previously permitted add-on payments for new technologies without demonstrating substantial clinical improvement.
The players
Centers for Medicare and Medicaid Services
A federal agency within the Department of Health and Human Services that manages Medicare and dictates national reimbursement policies for medical providers and device manufacturers.
Food and Drug Administration
A federal regulatory agency responsible for protecting public health by regulating medical devices and establishing the criteria for breakthrough status.
The details
Under the prior framework, breakthrough-designated products—ranging from triage algorithms to thrombectomy robots—could secure Medicare add-on payments without the typical burden of proving novel clinical efficacy. By removing these pathways, CMS requires manufacturers to align their devices with standard reimbursement criteria. Operators must now pivot toward generating more robust clinical data to maintain access to supplementary payments, as the expedited shortcut is no longer available to new market entrants.
Timeline
2020: Breakthrough devices gained access to special payment pathways.
2022: STAT's Breakthrough Device Tracker began tracking device status.
August 2026: CMS finalized the removal of special payment pathways.
October 2026: Special Medicare payment eligibility for new devices ends.
Market Landscape
This policy shift marks a departure from the rapid reimbursement support established by the FDA breakthrough device designation program. It aligns Medicare coverage more closely with traditional clinical evidence requirements, moving away from the expedited approval environment that dominated the sector since 2020.
Manufacturers and developers should audit their pipeline devices to determine if they will be subject to the new clinical evidence requirements before the October 2026 cutoff. Operators should consult with reimbursement counsel to adjust their financial forecasting and evidence-gathering strategies.
The takeaway
The end of expedited Medicare payments for breakthrough devices underscores a shift toward higher standards for clinical evidence in medical innovation. Operators should review their current R&D portfolios to confirm which projects now require more comprehensive data submissions to ensure future reimbursement.
Further reading
For broader trends regarding federal oversight, see the Healthcare section.
Source note: This article includes information reported by STAT.
Live Poll
Should medical devices receive expedited Medicare funding without proving substantial clinical improvement over existing alternatives?
